Tags : Biosimilar

Biosimilars

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights

Shots: Innovent to receive milestones for development and commercialization along with royalties on net sales of the therapy in the licensed territory. Etana is committed to launch Byvasda in Indonesia The collaboration will enable Byvsada to penetrate into a Southeast Asian market and allow Innovent to bolster its presence globally In Jan’2020, Innovent signed an […]Read More

Biosimilars

Kamada to Commercialize Three Biosimilar Products in Israel

Shots: Kamada signs an agreement with two undisclosed international pharmacies to commercialize three biosimilar product candidates in Israel. The two pharmaceutical companies will be responsible for the development, manufacturing, and supply of three products Following the approval from EMA and IMOH, the three products are expected to be launched in Israel b/w 2022 and 2024 […]Read More

Biosimilars

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada

Shots: Health Canada has authorized Hyrimoz on Nov 4, 2020 for marketing in Canada. Hyrimoz has been approved for use in all same indications as reference Humira, including rheumatology, gastroenterology and dermatology A patient support program will be available to patients treated with Hyrimoz providing guidance with reimbursement navigation, financial assistance, administrative support & education […]Read More

Biosimilars

Innovent’s Sulinno (biosimilar, adalimumab) Receive NMPA’s Approval for Polyarticular Juvenile

Shots: The NMPA has approved Sulinno for the treatment of pJIA which is the fourth approved indication of the therapy in China. Earlier, Sulinno was approved for RA, PS, and psoriasis The launch of Sulinno has provided more Chinese patients with high-quality and relatively affordable adalimumab injection, bringing hope and opportunities to more patients Sulinno […]Read More

Biosimilars

Genentech Files Complaint Against Centus Over Proposed Bevacizumab Biosimilar

Shots: Genentech filed a complaint in the Eastern District of Texas alleging that the proposed biosimilar to Avastin (bevacizumab) product infringes 10 US patents Genentech alleges that Centus and partners failed to disclose sufficient information about the proposed biosimilar to enable Genentech to do a sufficient analysis of potential patent infringements Centus has a BLA […]Read More